Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	105	81811			
iling Date		2006-06-02			
irst Named Inventor Koma		'asuhiko			
Art Unit	Т				
Examiner Name					
Attorney Docket Number		67-62020			

					U.S.I	PATENTS			Remove	
Examiner Initial*	er Cite No Patent Number Kind Code ¹ Issue Date Name of Patent of cited Docume		entee or Applicant ment	Releva	Columns,Lines whe ant Passages or Rele s Appear					
	1									
If you wis	h to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLK	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Publ	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	-
	1	WO 02 18418	wo			2001-08-23	UNIV VIRGINIA			
If you wis	h to a	l dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add	-
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Initials* No No (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue numbor(s), publisher, city and/or country where published.								ppropria ume-iss	ate), title of the item ue number(s),	Тя

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10581811
Filing Date		2006-06-02
First Named Inventor Koma		tsu, Yasuhiko
Art Unit		
Examiner Name		
Attorney Docket Number		46067-62020

	1		HE et al., "Mycobacterial heparin-binding hemagglutinin and laminin confer resistance to proteolysis." Proc Natl Acad Sci U S A. 2002 A			
	2	acety	NBRECHER et al., "Immunogenicity of homologous low density lipolation, or carbamylation; generation of antibodies specific for derive 1109-16.			
	3		duct Datasheet for ab/766" (retrieved on 2006-06-16) Retrieved fr framework/popups/popup_printable_ds.cfm/intAbID=7766>	om the Internet: <ur< td=""><td>L: http://www.abcam.</td><td></td></ur<>	L: http://www.abcam.	
	4		et al., "Correlation between histone lysine methylation and develop" Science. 2001 Sep 28;293(5539):2453-5.	mental changes at the	e chicken beta-globin	
	5		ER et al., "Location of seven post-translational modifications in rabb thyllysine, trimethyllysine, and glycerylphosphorylethanolamine." J			
6 FONZI et al., "Regulation of protein synthesis factor EF-1 alpha in Mucor racerrosus." Mol Ceil Biol. 1985 May,5 (5):1100-3.						
If you wis	h to a	dd add	ditional non-patent literature document citation information pl	ease click the Add I	outton Add	
			EXAMINER SIGNATURE			
Examiner	Sign	ture		Date Considered		\neg

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10581811
Filing Date		2006-06-02
First Named Inventor	Koma	tsu, Yasuhiko
Art Unit		
Examiner Name		
Attorney Docket Number		46067-62020

CERTIFICATION STATEMENT

Diagon con	37	CFR .	1 97	and	1 02	to	make the	appropriate	colortion/c	e)·

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CPR 1.97(e/t1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
-

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Charles P. Romano/	Date (YYYY-MM-DD)	2006-11-21
Name/Print	Charles P. Romano	Registration Number	56991

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleater and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.